Eli Lilly raises annual revenue expectation as GLP-1 drugs fuel growth

Eli Lilly raised its full-year revenue forecast after stronger-than-expected quarterly results, driven by robust demand for Mounjaro and Zepbound

Eli Lilly and Co posted better-than-expected quarterly results and raised its full-year revenue forecast on Wednesday, banking on sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs. 

Sales of diabetes drug Mounjaro rose 91 per cent to $9.94 billion, beating analysts’ estimates, while obesity drug Zepbound brought in $4.93 billion, compared with expectations of $4.73 billion.